Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Meredith

Showing results (41-50 of 42) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 42 results.
Heart (British Cardiac Society)|November 3, 2012
Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trialRoberto Diletti, Vasim Farooq, Chrysafios Girasis, et al.
JACC. Cardiovascular Interventions|December 24, 2011
Serial in vivo intravascular ultrasound-based echogenicity changes of everolimus-eluting bioresorbable vascular scaffold during the first 12 months after implantation insights from the ABSORB B trialSalvatore Brugaletta, Josep Gomez-Lara, Patrick W Serruys, et al.
Pageof 5

Showing results (41-50 of 42) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 42 results.
Heart (British Cardiac Society)|November 3, 2012
Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trialRoberto Diletti, Vasim Farooq, Chrysafios Girasis, et al.
JACC. Cardiovascular Interventions|December 24, 2011
Serial in vivo intravascular ultrasound-based echogenicity changes of everolimus-eluting bioresorbable vascular scaffold during the first 12 months after implantation insights from the ABSORB B trialSalvatore Brugaletta, Josep Gomez-Lara, Patrick W Serruys, et al.
Pageof 5